

The exercise period for NeoDynamics warrants of series T02 Begins today

Today, on November 11, 2023, the exercise period for warrants series T02 in NeoDynamics AB (publ) ("NeoDynamics" or the "Company") commences. The subscription price per share that is subscribed through exercise of warrants has been set to SEK 0.02 per share. The exercise period for the warrants lasts until December 1, 2023. If all warrants are exercised, NeoDynamics will receive approximately SEK 3.9 million before issue costs.

Summarized terms and conditions for warrants series T02:

- The exercise period for the warrants runs from and including November 20, 2023, to and including December 1, 2023.
- One (1) warrants of series T02 entitle the holder to subscribe for one (1) new ordinary share in the Company.
- Trading in warrants is ongoing to and including November 29, 2023. Warrants that are not exercised by December 1, 2023, expire without value.
- Holders of warrants who have their holdings nominee-registered must notify the exercise of warrants by contacting their respective nominee and follow the nominee's instructions regarding subscription and payment. This should take place well before December 1, 2023, as different nominees have different processing times.
- Holders of warrants who have their holdings directly registered must notify the exercise of warrants by filling in and submitting an application form for the exercise, so that the application form is received by the issuing agent, Nordic Issuing, no later than December 1, 2023. The application form is available on the Company's, the issuing agent's and Redeye AB's respective websites.
- If all warrants are exercised, NeoDynamics will receive approximately SEK 3.9 million before issue costs.
- Complete terms and conditions for the warrants are available on the Company's

Increase in the number of shares and share capital

Upon full utilization of all 192,813,110 Warrants series T02, the share capital will increase by a maximum of SEK 3,326,026.1475 to SEK 15,382,750.0140 SEK through the issuance of maximum of 192,813,110 new shares, resulting in that the total number of shares in the Company will increase from 698,940,514 to 891,753,624. Upon full utilization of all Warrants series T02, the dilution of the amounts to approximately 22 percent.

Advisers

Redeye AB is a financial advisor in connection with the Rights Issue. Advokatfirman Lindahl KB acts as legal advisor to NeoDynamics in connection with the Rights Issue. Nordic Issuing AB acts as the issuing agent in connection with the Rights Issue.

For further information, please contact:

Anna Eriksrud, CEO NeoDynamics AB, phone 0708 444 966 or e-mail anna.eriksrud@neodynamics.com

Aaron Wong, CFO NeoDynamics AB, phone 0735 972 011 or e-mail aaron.wong@neodynamics.com

About NeoDynamics

NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of cancer. The company's first product NeoNavia®, a new innovative pulse biopsy system for ultrasound-guided tissue sampling, is currently being introduced to the market. NeoNavia® is CE approved, and in September 2022, received a 510k approval from the FDA. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in Europe and launches in USA during 2023. NeoDynamic's shares are listed on Nasdaq First North Growth Market Stockholm (ticker: NEOD). The company's Certified Adviser is Redeye AB.

About NeoNavia®

NeoNavia® is the trade name for the complete biopsy system intended for use in ultrasound-guided sampling. NeoNavia® consists of a base unit, a hand unit, and three types of biopsy needles. The pulse technology drives the respective needle type, which facilitates needle insertion and placement in the suspected tumor. The system is designed to offer physicians and patients precise and robust tissue sampling for accurate diagnosis and individualized treatment.

About the pulse technology

The patented pulse technology is based on a pneumatically driven mechanism that enables high precision and control when inserting and positioning the biopsy needle, regardless of tissue type. The pneumatic drive unit that generates pulses is located in a hand-held instrument. With power from the base unit, the hand-held driver accelerates the biopsy needle with great control, even over short distances, enabling a distinct step-by-step insertion without affecting the surrounding tissue. This enables good access and flexibility in sampling, even in tiny and tricky localized tumors.

For more information, please visit [Neodynamics.com](https://www.neodynamics.com).

The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in NeoDynamics. The invitation to the persons concerned to subscribe for units consisting of shares and warrants in NeoDynamics has only been made through the prospectus published by NeoDynamics on July 31, 2023, and through the supplement prospectuses published by NeoDynamics on August 11, 2023. The prospectuses have been approved and registered by the Swedish Financial Supervisory Authority and have been published on the Company's website, www.neodynamics.com.

The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

Attachments

[The exercise period for NeoDynamics warrants of series T02 Begins today](#)